Magalie Ladouceur

Magalie Ladouceur 2018-01-04T10:34:02+00:00

– Since 2010: ACHD Cardiologist, Hôpital Européen Georges Pompidou and medical coordinator of transition clinic (Necker-HEGP)

– PhD (2013-2016): Myocardial function and imaging, U970, Paris Cardiovascular Research Center, PARCC, Paris Descartes University, Sorbone Cité.

–  Specialist register (2006 – 2009): Adult Congenital Heart Disease, Cardiology department, Hôpital Européen Georges Pompidou, Paris

– Specialist register (2005-2006): Pediatric Cardiology department, Necker, Paris

–  Cardiology residency : Assistance Publique des Hôpitaux de Paris


“Pregnancy – too high risk for all or manageable in selected patients?”

Pulmonary arterial hypertension (PAH) in pregnant women is still associated with a prohibitive high mortality and morbidity, especially during post-partum period. For this reason, women with PAH should still be advised against pregnancy, and be advised for effective contraceptive methods. The risks associated with pregnancy must be emphasised and counselling offered to women at the time of PAH diagnosis and to women with PAH who become pregnant. In this case, early termination should be firstly discussed.

However, recent data indicate that morbidity and mortality during pregnancy and after birth have improved for PAH patients. This improvement may be explained by the multidisciplinary approach in PAH expert centers, continuation or early introduction of targeted PAH therapy during pregnancy, as well as an early planned delivery. Moreover, some women with mild pulmonary hypertension or favorable functional class may have a better prognosis.